32.24
-1.02(-3.07%)
Currency In USD
| Previous Close | 33.26 |
| Open | 33.13 |
| Day High | 33.49 |
| Day Low | 31.99 |
| 52-Week High | 46.48 |
| 52-Week Low | 25.28 |
| Volume | 1.76M |
| Average Volume | 1.99M |
| Market Cap | 5.12B |
| PE | 11.64 |
| EPS | 2.77 |
| Moving Average 50 Days | 33.91 |
| Moving Average 200 Days | 34.98 |
| Change | -1.02 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $2,367.11 as of November 09, 2025 at a share price of $32.24. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $1,116.34 as of November 09, 2025 at a share price of $32.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
GlobeNewswire Inc.
Oct 31, 2025 11:30 AM GMT
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ETNEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to disc
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
GlobeNewswire Inc.
Oct 28, 2025 11:30 AM GMT
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
GlobeNewswire Inc.
Sep 24, 2025 1:10 PM GMT
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatme